Categories
Business Coronavirus Headlines Marketing News

Lennox-Gastaut Syndrome Drug Market is Slated to Witness Tremendous Growth || Leading Players – GW Pharmaceuticals plc, Johnson & Johnson Services, Inc, GlaxoSmithKline plc, Zogenix, H. Lundbeck A/S

Lennox-Gastaut Syndrome Drug Market

A proficient data and brilliant forecasting techniques used in this Lennox-Gastaut Syndrome Drug Market report are synonymous with accurateness and correctness. The document is a meticulous analysis of existing scenario of the market, which covers several market dynamics. This market research report endows with the plentiful insights and business solutions that will support to stay ahead of the competition. The most precise way to forecast what future holds is to understand the trend today and hence Lennox-Gastaut Syndrome Drug Marketing report has been structured by chewing over numerous fragments of the present and upcoming market scenario.

Get Exclusive Sample Copy of This Report Here  https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-lennox-gastaut-syndrome-drug-market

This Lennox-Gastaut Syndrome Drug Market report is the consequence of incessant efforts lead by clued-up forecasters, innovative analysts and bright researchers who indulge in detailed and attentive research on different markets, trends and emerging opportunities in the consecutive direction for the business needs. Company snapshot, geographical presence, product portfolio, and recent developments are taken into account for studying the company profiles that are part of this report. Quality and transparency has been strictly maintained while carrying out research studies to offer an exceptional market research report for a niche. A thoughtful knowledge of industrial unanimity, market trends and incredible techniques via this Lennox-Gastaut Syndrome Drug Market report gives an upper hand in the market.

Global Lennox-Gastaut syndrome drug market is growing at a substantial CAGR in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the rising population with risk factors for LGS, the growing prevalence of infectious diseases such as encephalitis and meningitis will further increase the risk of the development of LGS, initiatives taken by government and non-governmental organizations for raising awareness about this syndrome, increasing investment of biotechnology and pharmaceutical industries in R&D and increasing healthcare expenditure are some of the factors fueling the market growth.

The key market players in the global Lennox-Gastaut syndrome drug market are Pfizer Inc, Sunovion Pharmaceuticals Inc, Novartis AG, Abbott, Eisai Co., Ltd, INSYS THERAPEUTICS, INC, GW Pharmaceuticals plc, Johnson & Johnson Services, Inc, GlaxoSmithKline plc, Zogenix, H. Lundbeck A/S, Bausch Health, Supernus Pharmaceuticals, Inc, UCB Pharma Ltd, Sanofi, Marinus Pharmaceuticals, Inc, Teva Pharmaceutical Industries Ltd among others.

Browse Detailed TOC Here https://www.databridgemarketresearch.com/toc?dbmr=global-lennox-gastaut-syndrome-drug-market

Market Definition: Global Lennox-Gastaut Syndrome Drug Market

Lennox-Gastaut syndrome (LGS) is a rare type of childhood onset epilepsy that progresses during early stages of childhood. Patients with this syndrome have developmental delay, behavioral problems and different types of seizures such as atonic, tonic and atypical absence seizures.

This syndrome is associated with several gene mutations, perinatal insults, congenital infections, brain tumors/malformations and genetic disorders such as tuberous sclerosis and West syndrome.

According to National Organization for Rare Disorders (NORD), it estimates that Lennox-Gastaut syndrome occur in 1-28 people per 100,000 and it accounts for 1-4 percent of all cases of childhood epilepsy. The annual incidence of this syndrome in children is estimated to be 2 per 100,000 children.

Segmentation: Global Lennox-Gastaut Syndrome Drug Market

Lennox-Gastaut Syndrome Drug Market : By Mechanism of Action

  • Anti-Epileptics
  • Anticonvulsants
  • Others

Lennox-Gastaut Syndrome Drug Market : By Drugs

  • Valproic Acid
  • Topiramate
  • Felbamate
  • Rufinamide
  • Lamotrigine
  • Others

Lennox-Gastaut Syndrome Drug Market : By Treatment

  • Medication
  • Dietary Therapy
  • Surgery

Lennox-Gastaut Syndrome Drug Market : By Route of Administration

  • Oral
  • Parenteral

Lennox-Gastaut Syndrome Drug Market : By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Lennox-Gastaut Syndrome Drug Market : By End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics

Lennox-Gastaut Syndrome Drug Market : By Geography

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

Lennox-Gastaut Syndrome Drug Market Drivers

  • Rising population with risk factors for LGS is driving the market growth
  • Growing prevalence of infectious diseases such as encephalitis and meningitis increases the risk of the development of LGS which acts as a market driver
  • Increasing investment of biotechnology and pharmaceutical industries in R&D is enhancing the market growth
  • Initiatives taken by government and non-governmental organizations for raising awareness amongst people about this disorder also boost the market growth
  • Increasing global healthcare expenditure drives the market growth

Lennox-Gastaut Syndrome Drug Market Restraints

  • Side effects associated with available treatment is hampering the market growth
  • High cost of treatment available is restraining the market growth
  • Lack of availability of essential services in remote areas acts as a market restraint

Key Developments in the Lennox-Gastaut Syndrome Drug Market

  • In November 2018, Aquestive Therapeutics, Inc received the U.S FDA approval for Sympazan (clobazam) for the treatment of Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older. Patients with LGS have difficulty in swallowing tablets or large volumes of oral suspension, because of physical limitations or compliance issues, Sympazan oral film is a cost effective treatment and will overcome difficulties in those patients who faces difficulty in swallowing tablets
  • In June 2018, GW Pharmaceuticals plc received the U.S FDA approval for Epidiolex (cannabidiol), oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome in patients two years of age and older. This approval proves that properly evaluating the active ingredients contained in marijuana can lead to important medical therapies

Opportunities in the Lennox-Gastaut Syndrome Drug Market Report :

  1. Comprehensive quantitative analysis of the industry is provided for the period of 2020-2026 to assist stakeholders to capitalize on the prevailing market opportunities.
  2. Comprehensive analysis of the factors that drive and restrict the market growth is provided in the Lennox-Gastaut Syndrome Drug Market report.
  3. Extensive analysis of the key segments of the industry helps in understanding the trends in types of point of care test across regional.
  4. Extensive analysis of the key segments of the industry helps in understanding the trends in types of point of care test across Global.

Inquire Before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-lennox-gastaut-syndrome-drug-market

About Data Bridge Market Research:

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475
Mail: [email protected]